This is a preview of subscription content, log in via an institution to check access.
Reference
Girouard MP, et al. The cost-effectiveness and budget impact of two-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States. Clinical Infectious Diseases : 9 Dec 2015. Available from: URL: http://doi.org/10.1093/cid/civ981
Rights and permissions
About this article
Cite this article
Dolutegravir/lamivudine for HIV infection could save costs. PharmacoEcon Outcomes News 744, 11 (2016). https://doi.org/10.1007/s40274-016-2715-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-2715-z